Market Overview

Gilead Misses Revenue Estimates, Cuts Guidance

Gilead Misses Revenue Estimates, Cuts Guidance
Related GILD
Najarian Brothers See Unusual Options Activity In Procter & Gamble And Gilead
With $36.7B In Cash, Bank of America Expects Gilead To Shop For Complements To Drug Pipeline
Biotechs: Still Well Placed For More Gains (Seeking Alpha)

Gilead Sciences, Inc. (NASDAQ: GILD) released its Q2 results after market close on Monday. Earnings per share came in above Wall Street consensus expectations, however, the company lowered sales guidance, sending shares down 4 percent.

Gilead reported EPS of $3.08 and revenues of $7.776 billion. Analyst consensus had an EPS estimate of $3.02 and $7.79 billion in revenue. The company cut FY16 sales guidance from $30-$31 billion to $29.5-$30.5 billion.

Related Link: Biotech In The Earnings Spotlight: Amgen, Celgene, Gilead Sciences

HIV and other antiviral product sales were $3.1 billion compared to $2.7 billion year-over-year, primarily due to increases in TAF based products such as Genvoya and Descovy.

The report came after Gilead reported multiple positive developments in July:

  • July 8: Gilead received European Commission authorization for Epclusa.
  • July 14: Epclusa received approval in Canada
  • July 21: Gilead's Odefsey met primary 48-week objective in two phase 3b studies.

At time of writing, Gilead traded at $85.42 in Monday's after-hours session, down 3.3 percent.

Posted-In: Earnings News Guidance After-Hours Center Movers Best of Benzinga


Related Articles (GILD)

View Comments and Join the Discussion!